Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Intervention not reported

Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy

The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).

1 finding from 1 review

Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.25 [0.93, 1.7]
7 studies · 2185 participants
Moderate

Carisbamate vs placebo

Treatment withdrawal · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.32 [0.82, 2.12]
4 studies · 2211 participants
Very low

Vigabatrin vs placebo

Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin add‐on therapy for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 2.86 [1.25, 6.55]
4 studies · 370 participants
Very low